SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Traders are closely monitoring the upcoming Federal Reserve meeting, with high expectations for a rate hike as sentiment remains bearish amid concerns over rising Treasury yields, inflation, and oil price volatility. While some participants weigh the potential impact of AI development slowdowns and ongoing geopolitical tensions on market stability, the conversation remains largely focused on the Fed's policy trajectory and its influence on broader market performance.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The conversation is dominated by concerns over rising Treasury yields, which briefly topped 5%, alongside ongoing uncertainty regarding AI-sector development and expectations for a Federal Reserve rate hike. Market participants are debating whether current volatility represents a cooling phase or a potential crash, with a notable split between those reacting to macro headwinds and those betting on a continued market recovery.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin shares are facing significant volatility as traders debate whether the stock is being manipulated by institutional accumulation or if macroeconomic headwinds and analyst price target downgrades are suppressing the price. The community remains divided, with many bullish investors holding for a recovery toward previous highs, while others express frustration over the stock's inability to maintain gains despite strong fundamentals and cash flow.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors focus on the upcoming mid-November FDA PDUFA date for its drug ivonescimab. The community remains divided, with many highlighting recent clinical trial data and strong insider support, while others urge caution regarding the reliance on China-based study results and potential short-term volatility.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders react to surging Treasury yields hitting multi-year highs and persistent concerns over inflation, oil prices, and the upcoming Federal Reserve interest rate decision. Market participants remain deeply divided on the outlook for long-term bonds, with many debating whether the current selloff presents a structural shift or a tactical buying opportunity.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

Traders are actively debating the viability of using UVXY as a volatility hedge amidst geopolitical tensions and economic concerns, with many expressing frustration over its structural decay and perceived lack of correlation to spot VIX. While some market participants are betting on a volatility spike, others warn that its design as a leveraged futures-based product makes it a poor long-term holding prone to constant value erosion.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as traders speculate on positive guidance updates and clinical progress, following recent healthcare conference appearances and anticipation of upcoming Phase 2 NSCLC trial data. While the stock has seen significant momentum, community sentiment remains focused on the expectation that the company's solid tumor platform and clinical milestones will drive long-term value.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is trending as investors discuss a newly announced partnership with Supermicro to integrate high-density rack-scale servers into the company's Secure AI Factory platform. While some traders are optimistic about the potential for enterprise AI growth, many others remain frustrated by the stock's recent stagnant price action and weak momentum following its earnings report.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as investors weigh clinical data updates on its oncology pipeline against the company's recent leadership transition, with some traders expressing disappointment over the upcoming departure of the founders while others remain optimistic about the late-stage trial catalysts.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is experiencing volatility and downward pressure as traders weigh the impact of rising Treasury yields, higher oil prices, and uncertainty regarding Federal Reserve interest rate policy. The community is divided between those interpreting recent price action as a buying opportunity in a long-term uptrend and those concerned that the index is vulnerable to further downside, particularly given its technical weakness and sensitivity to macro headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
